simvastatin; sitagliptin phosphate - Profile

What are the generic sources for simvastatin; sitagliptin phosphate and what is the scope of freedom to operate?

Simvastatin; sitagliptin phosphate is the generic ingredient in one branded drug marketed by Merck Sharp Dohme and is included in one NDA. There is one patent protecting this compound and three Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Simvastatin; sitagliptin phosphate has fifty-two patent family members in forty countries.

Summary for simvastatin; sitagliptin phosphate

International Patents:	52
US Patents:	1
Tradenames:	1
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for simvastatin; sitagliptin phosphate

Paragraph IV (Patent) Challenges for SIMVASTATIN; SITAGLIPTIN PHOSPHATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
JUVISYNC	Tablets	simvastatin; sitagliptin phosphate	50 mg/10 mg 50 mg/20 mg 50 mg/40 mg	202343	1	2012-11-06
JUVISYNC	Tablets	simvastatin; sitagliptin phosphate	100 mg/20 mg	202343	1	2012-06-25
JUVISYNC	Tablets	simvastatin; sitagliptin phosphate	100 mg/10 mg and 100 mg/40 mg	202343	1	2012-06-19

US Patents and Regulatory Information for simvastatin; sitagliptin phosphate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Merck Sharp Dohme	JUVISYNC	simvastatin; sitagliptin phosphate	TABLET;ORAL	202343-004	Sep 18, 2012		DISCN	Yes	No					Y
Merck Sharp Dohme	JUVISYNC	simvastatin; sitagliptin phosphate	TABLET;ORAL	202343-001	Oct 7, 2011		DISCN	Yes	No					Y
Merck Sharp Dohme	JUVISYNC	simvastatin; sitagliptin phosphate	TABLET;ORAL	202343-005	Sep 18, 2012		DISCN	Yes	No					Y
Merck Sharp Dohme	JUVISYNC	simvastatin; sitagliptin phosphate	TABLET;ORAL	202343-002	Oct 7, 2011		DISCN	Yes	No					Y
Merck Sharp Dohme	JUVISYNC	simvastatin; sitagliptin phosphate	TABLET;ORAL	202343-006	Sep 18, 2012		DISCN	Yes	No					Y
Merck Sharp Dohme	JUVISYNC	simvastatin; sitagliptin phosphate	TABLET;ORAL	202343-003	Oct 7, 2011		DISCN	Yes	No					Y

Expired US Patents for simvastatin; sitagliptin phosphate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Merck Sharp Dohme	JUVISYNC	simvastatin; sitagliptin phosphate	TABLET;ORAL	202343-005	Sep 18, 2012
Merck Sharp Dohme	JUVISYNC	simvastatin; sitagliptin phosphate	TABLET;ORAL	202343-005	Sep 18, 2012
Merck Sharp Dohme	JUVISYNC	simvastatin; sitagliptin phosphate	TABLET;ORAL	202343-001	Oct 7, 2011
Merck Sharp Dohme	JUVISYNC	simvastatin; sitagliptin phosphate	TABLET;ORAL	202343-006	Sep 18, 2012
Merck Sharp Dohme	JUVISYNC	simvastatin; sitagliptin phosphate	TABLET;ORAL	202343-003	Oct 7, 2011
Merck Sharp Dohme	JUVISYNC	simvastatin; sitagliptin phosphate	TABLET;ORAL	202343-004	Sep 18, 2012
Merck Sharp Dohme	JUVISYNC	simvastatin; sitagliptin phosphate	TABLET;ORAL	202343-002	Oct 7, 2011

International Patents for simvastatin; sitagliptin phosphate

Country	Patent Number	Title	Estimated Expiration
Argentina	044705	SAL DE ACIDO FOSFORICO DE UN INHIBIDOR DE LA DIPEPTIDIL PEPTIDASA -IV
Argentina	094185	SAL DE ACIDO FOSFORICO DE UN INHIBIDOR DE LA DIPEPTIDIL PEPTIDASA-IV
Austria	373003
Australia	2004253889	Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
Brazil	PI0411726	composto, monoidrato, sal, composição farmacêutica, método para o tratamento de diabetes tipo 2, processo para preparar o composto, uso do composto, e, processo para a preparação do monoidrato cristalino
Canada	2529400	SEL D'ACIDE PHOSPHORIQUE D'UN INHIBITEUR DE LA DIPEPTIDYL PEPTIDASE IV (PHOSPHORIC ACID SALT OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR)
China	100430397

Supplementary Protection Certificates for simvastatin; sitagliptin phosphate

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0720599	26/2005	Austria		PRODUCT NAME: EZETIMIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON KOMBINIERT MIT SIMVASTATIN; NAT. REGISTRATION NO/DATE: 1-25673 - 1-25676 20041228; FIRST REGISTRATION: DE 58874.00.00 - 58874.03.00; 58878.00.00 - 20040402
0720599	122004000026	Germany		PRODUCT NAME: EZETIMIB ODER PHARMAZEUTISCH ANNEHMBARE SALZE DAVON IN KOMBINATION MIT SIMVASTATIN; NAT. REGISTRATION NO/DATE: 58866.00.00 58866.01.00 58866.02.00 58866.03.00 58870.00.00 58870.01.00 58870.02.00 58870.03.00 58874.00.00 58874.01.00 58874.02.00 58874.03.00 58878.00.00 58878.01.00 58878.02.00 58878.03.00 20040402 FIRST REGISTRATION: DE 58866.00.00 - 58866.03.00 58870.00.00 - 58870.03.00 58874.00.00 - 58874.03.00 58878.00.00 - 58878.03.00 20040402
0720599	SPC/GB05/010	United Kingdom		PRODUCT NAME: EZETIMIBE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF IN COMBINATION WITH SIMVASTATIN; REGISTERED: DE 58874.00.00 20040402; DE 58874.01.00 20040402; DE 58874.02.00 20040402; DE 58874.03.00 20040402; DE 58878.00.00 20040402; DE 58878.01.00 20040402; DE 58878.02.00 20040402; DE 58878.03.00 20040402; DE 58866.00.00 20040402; DE 58866.01.00 20040402; DE 58866.02.00 20040402; DE 58866.03.00 20040402; DE 58870.00.00 20040402; DE 58870.01.00 20040402; DE 58870.02.00 20040402; DE 58870.03.00 20040402; UK PL 19945/0003 20041118; UK PL 19945/0004 20041118; UK PL 19945/0005 20041118; UK PL 19945/0006 20041118; UK PL 19945/0007 20041118; UK PL 19945/0008 20041118; UK PL 19945/0009 200411

Investment Scenario and Fundamentals Analysis for Simvastatin and Sitagliptin Phosphate

Last updated: February 21, 2026

What is the current market landscape for simvastatin and sitagliptin phosphate?

Simvastatin and sitagliptin phosphate are established drugs with significant market presence. Simvastatin, a statin used for cholesterol management, generated global revenues estimated at $4.5 billion in 2022. Sitagliptin phosphate, a DPP-4 inhibitor indicated for type 2 diabetes, achieved approximately $6.4 billion in annual sales during the same year. Market dynamics are driven by patent expirations, generic competition, and increasing demand for chronic disease therapies.

How do patent statuses and generic competition influence market potential?

Simvastatin

• Patent expiration occurred in 2012 in the U.S., leading to widespread generic entry.
• Generic versions hold over 90% of the U.S. statin market.
• Future revenues depend on brand-specific formulations or combinations not yet off patent.

Sitagliptin Phosphate

• Patent protection expired in 2022.
• Generic versions now dominate the market.
• Limited pricing power and pressure on margins expected.

Impact

Patent expirations significantly compress revenues; companies investing in formulations or combination products may mitigate this. Market saturation limits growth potential for these off-patent drugs.

What are the current R&D and regulatory environments?

• Both drugs have well-established safety profiles and market approval.
• New formulations or delivery mechanisms are under exploration; for example, fixed-dose combinations.
• Regulatory pathways for generics are streamlined; for innovative formulations, new clinical data is required, prolonging approval cycles.

What are the key investment risks?

• Patent cliffs: Lead to rapid revenue decline post-expiry.
• Generic entry: Reduces profit margins.
• Market saturation: Limits growth prospects.
• Pipeline innovation: The lack of new indications or formulations could diminish future valuations.
• Regulatory hurdles: New formulations may face delays.

How do financial metrics compare?

Indicator	Simvastatin (post-2012 generics)	Sitagliptin (post-2022 generics)
Annual sales (2022)	~$4.5 billion	~$6.4 billion
Market share (U.S.)	High for generics (~90%)	Dominated by generics
Patent status	Off patent, widespread generics	Off patent, widespread generics
R&D investment (est.)	Low, focus on formulations	Low, focus on formulations

What strategic opportunities exist?

• Development of specialty formulations or fixed-dose combinations can create value.
• Entry into emerging markets with expanding healthcare access.
• Focus on biosimilars or alternative delivery systems may unlock growth.

What are the key drivers for long-term value?

• Innovation in drug delivery or indications.
• Market expansion in underserved regions.
• Licensing agreements for proprietary formulations.

Final assessment

Investing in simvastatin and sitagliptin phosphate requires weighing market maturity against potential for product differentiation. While generic competition constrains revenue growth, opportunities exist in formulation innovation and market expansion. Companies with active pipelines in these areas can sustain or increase their valuation despite patent expiries.

Key Takeaways

• Both drugs are mature with substantial market share but face declining revenues due to patent expiries.
• Growth prospects hinge on reformulations, combination therapies, and geographic expansion.
• R&D focus on innovation can offset generic competition risks.
• Market saturation limits upside unless new indications or delivery methods emerge.
• Strategic partnerships and licensing opportunities may enhance future value.

FAQs

1. What is the primary risk of investing in off-patent drugs like simvastatin and sitagliptin?
Patent expiration leads to generic competition, reducing profit margins and revenue streams.

2. Can reformulating these drugs restore profitability?
Yes; developing new formulations or fixed-dose combinations can differentiate products and extend lifecycle.

3. How do emerging markets influence the outlook for these drugs?
They offer growth opportunities due to increasing prevalence of metabolic conditions and lower generic penetration.

4. What regulatory challenges exist for developing innovative formulations?
New formulations require clinical trials and regulatory approval processes, which can delay market entry.

5. Is there any potential for pipeline development around these drugs?
Limited, as both are established molecules. Future potential lies more in new delivery platforms or combination therapies.

References

[1] IQVIA, "2022 The Global Use of Medicine in 2022," IQVIA Institute.
[2] EvaluatePharma, "Worldwide Pharmaceutical Sales Data," 2022.
[3] U.S. FDA, "Patent and Exclusivity Data," 2023.
[4] MarketWatch, "Simvastatin Market Analysis," 2022.
[5] Catalyst Pharmaceuticals, "Market Access and Strategy Review," 2022.